Jason M. Hafron, MD, CMO

Articles by Jason M. Hafron, MD, CMO

Optimization of Genetic Testing for mCRPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

December 9th 2021

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.

Sequencing Therapy for mCRPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

December 9th 2021

Daniel P. Petrylak, MD, leads the discussion on sequencing treatment for a patient with mCRPC, such as in case 2, who progresses on docetaxel therapy.

Role of PSMA PET Imaging in mCRPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

December 2nd 2021

Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.

Patient Case #2: Choosing Optimal Therapy in mCRPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

December 2nd 2021

Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.

Treatment Options for High-Volume mCNPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

November 24th 2021

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

Role of Conventional Imaging vs PSMA PET in mCNPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

November 24th 2021

A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.

Patient Case #1: Treatment Selection in mCNPC

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

November 18th 2021

Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.

Polling Questions: Advanced Prostate Cancer

ByRaoul S. Concepcion, MD, FACS,Jason M. Hafron, MD, CMO,Daniel P. Petrylak, MD,Oliver Sartor, MD,Leonard G. Gomella, MD

November 18th 2021

Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.